Chemistry:CORT-108297
From HandWiki
CORT-108297, also known as ADS-108297, is a nonsteroidal selective glucocorticoid receptor modulator (SEGRM) with mixed glucocorticoid and antiglucocorticoid actions which is under development for the treatment of Alzheimer's disease, cognition disorders, memory disorders, and post-traumatic stress disorder (PTSD).[1][2][3][4] It was also being developed for treatment of other psychiatric disorders and weight gain, but development for these indications was discontinued.[1] The drug is taken by mouth.[1] As of November 2022, CORT-108297 is in phase 2 clinical trials for the aforementioned active indications.[1][2]
See also
- Dagrocorat (PF-00251802)
- Dazucorilant (CORT-113176)
- Miricorilant (CORT-118335)
- Relacorilant (CORT-125134)
References
- ↑ 1.0 1.1 1.2 1.3 "CORT 108297". 29 November 2022. https://adisinsight.springer.com/drugs/800028115.
- ↑ 2.0 2.1 "Delving into the Latest Updates on CORT-108297 with Synapse". 27 September 2025. https://synapse.patsnap.com/drug/5658e833a86b4461879c424aa73dac6a.
- ↑ "Corticosteroid Action in the Brain: The Potential of Selective Receptor Modulation". Neuroendocrinology 109 (3): 266–276. 2019. doi:10.1159/000499659. PMID 30884490.
- ↑ "A patent review of anticancer glucocorticoid receptor modulators (2014-present)". Expert Opinion on Therapeutic Patents 30 (5): 313–324. May 2020. doi:10.1080/13543776.2020.1740206. PMID 32148111.
 |  |
